However, since the inhibitory concentration was almost 900-fold lower than the CC50, it is feasible to consider a strategy of furin inhibition, possibly in combination with TMPRSS-inhibtors, as a therapeutic option for COVID-19 patients (reviewed in [75,76]). This evidence concerns the gene FURIN and COVID-19.